药械

订阅

MedSci主页 / 所有栏目 / 药械

新药研发利器PROTAC技术全面解析：原理，历史，优势，设计，挑战，机遇与下一代PROTAC技术

2021-08-29 张浩 药学速览

PROTAC
关注

目前临床使用的大多数药物其治疗方法都是基于小分子的，并利用“占据驱动”作用模式抑制蛋白的功能，发挥治疗疾病的作用。不同于传统的小分子抑制剂和拮抗剂，蛋白降解剂技术由于其能够诱导

在过去的几十年里，小分子靶向药在延长患者生存期和改善患者生存质量上已经取得了巨大的成功。但是传统的小分子靶向药只能靶向大约 20%的蛋白，仍有大量的无酶功能的蛋白质，如转录因子、支架蛋白，或者与内源性的配体有很强结合力的蛋白(如 Ras等), 很难被传统小分子药物靶向。这类“不可成药”靶点的药物研发极具挑战，而基于蛋白降解的 PROTAC (Proteolysis-Targeting Chimera)技术在靶向不可成药靶点方面展现出了巨大的潜力。在细胞治疗、抗体药和基因编辑等新兴技术风头正盛的今天，PROTAC技术有望带领小分子药物重回巅峰。在此，我们将为大家介绍PROTAC的技术原理、优势。同时，我们将回顾在药物发现过程中有关蛋白靶向降解的经验教训，并讨论PROTAC在癌症治疗中面临的挑战和机遇。 ▉ PROTAC概述 PROTAC (Proteolysis Targeting Chimeras，蛋白降解靶向联合体)的概念最早是在2001年由Crews等人提出，能够利用机体内天然存在的蛋白清理系统，降低蛋白水平而非抑制蛋白的功能，发挥治疗疾病的目的。PROTAC技术经过20

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2121874, encodeId=709921218e4f3, content=新药研发利器<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>技术全面解析<a href='/topic/show?id=f259105e132a' target=_blank style='color:#2F92EE;'>#蛋白降解剂#</a>是十分热门的领域，事实上，很多老药现在发现实际上也是PROTAC类，如<a href='/topic/show?id=553b639416e' target=_blank style='color:#2F92EE;'>#氟维司群#</a>，<a href='/topic/show?id=21d764465c7' target=_blank style='color:#2F92EE;'>#沙利度胺#</a><a href='/topic/show?id=c34d64e47d1' target=_blank style='color:#2F92EE;'>#泊马度胺#</a>。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC), TopicDto(id=105713, encryptionId=f259105e132a, topicName=蛋白降解剂), TopicDto(id=63941, encryptionId=553b639416e, topicName=氟维司群), TopicDto(id=64465, encryptionId=21d764465c7, topicName=沙利度胺), TopicDto(id=64747, encryptionId=c34d64e47d1, topicName=泊马度胺)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun Mar 26 11:39:51 CST 2023, time=2023-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1672991, encodeId=c30416e29917e, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Mon Oct 18 04:13:08 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033744, encodeId=e1ed2033e44cf, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Mon Apr 18 22:13:08 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300486, encodeId=e67f1300486f4, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Tue Aug 31 12:13:08 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526286, encodeId=aa8315262869a, content=<a href='/topic/show?id=84d03692056' target=_blank style='color:#2F92EE;'>#历史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36920, encryptionId=84d03692056, topicName=历史)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=131011702315, createdName=cathymary, createdTime=Tue Aug 31 12:13:08 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602381, encodeId=8005160238185, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Aug 31 12:13:08 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012714, encodeId=518e1012e1488, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Mon Aug 30 04:56:54 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012657, encodeId=fd3f101265e7f, content=<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>这是目前看到信息量最大，内容最全，也最新的一篇有关PROTAC新药开发的文章，值得收藏！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 29 22:07:26 CST 2021, time=2021-08-29, status=1, ipAttribution=)]
    2023-03-26 侠胆医心 来自上海

    新药研发利器#PROTAC#技术全面解析#蛋白降解剂#是十分热门的领域，事实上，很多老药现在发现实际上也是PROTAC类，如#氟维司群#，#沙利度胺##泊马度胺#。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2121874, encodeId=709921218e4f3, content=新药研发利器<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>技术全面解析<a href='/topic/show?id=f259105e132a' target=_blank style='color:#2F92EE;'>#蛋白降解剂#</a>是十分热门的领域，事实上，很多老药现在发现实际上也是PROTAC类，如<a href='/topic/show?id=553b639416e' target=_blank style='color:#2F92EE;'>#氟维司群#</a>，<a href='/topic/show?id=21d764465c7' target=_blank style='color:#2F92EE;'>#沙利度胺#</a><a href='/topic/show?id=c34d64e47d1' target=_blank style='color:#2F92EE;'>#泊马度胺#</a>。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC), TopicDto(id=105713, encryptionId=f259105e132a, topicName=蛋白降解剂), TopicDto(id=63941, encryptionId=553b639416e, topicName=氟维司群), TopicDto(id=64465, encryptionId=21d764465c7, topicName=沙利度胺), TopicDto(id=64747, encryptionId=c34d64e47d1, topicName=泊马度胺)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun Mar 26 11:39:51 CST 2023, time=2023-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1672991, encodeId=c30416e29917e, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Mon Oct 18 04:13:08 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033744, encodeId=e1ed2033e44cf, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Mon Apr 18 22:13:08 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300486, encodeId=e67f1300486f4, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Tue Aug 31 12:13:08 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526286, encodeId=aa8315262869a, content=<a href='/topic/show?id=84d03692056' target=_blank style='color:#2F92EE;'>#历史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36920, encryptionId=84d03692056, topicName=历史)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=131011702315, createdName=cathymary, createdTime=Tue Aug 31 12:13:08 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602381, encodeId=8005160238185, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Aug 31 12:13:08 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012714, encodeId=518e1012e1488, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Mon Aug 30 04:56:54 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012657, encodeId=fd3f101265e7f, content=<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>这是目前看到信息量最大，内容最全，也最新的一篇有关PROTAC新药开发的文章，值得收藏！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 29 22:07:26 CST 2021, time=2021-08-29, status=1, ipAttribution=)]
    2021-10-18 hongbochen

    #解析#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2121874, encodeId=709921218e4f3, content=新药研发利器<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>技术全面解析<a href='/topic/show?id=f259105e132a' target=_blank style='color:#2F92EE;'>#蛋白降解剂#</a>是十分热门的领域，事实上，很多老药现在发现实际上也是PROTAC类，如<a href='/topic/show?id=553b639416e' target=_blank style='color:#2F92EE;'>#氟维司群#</a>，<a href='/topic/show?id=21d764465c7' target=_blank style='color:#2F92EE;'>#沙利度胺#</a><a href='/topic/show?id=c34d64e47d1' target=_blank style='color:#2F92EE;'>#泊马度胺#</a>。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC), TopicDto(id=105713, encryptionId=f259105e132a, topicName=蛋白降解剂), TopicDto(id=63941, encryptionId=553b639416e, topicName=氟维司群), TopicDto(id=64465, encryptionId=21d764465c7, topicName=沙利度胺), TopicDto(id=64747, encryptionId=c34d64e47d1, topicName=泊马度胺)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun Mar 26 11:39:51 CST 2023, time=2023-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1672991, encodeId=c30416e29917e, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Mon Oct 18 04:13:08 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033744, encodeId=e1ed2033e44cf, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Mon Apr 18 22:13:08 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300486, encodeId=e67f1300486f4, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Tue Aug 31 12:13:08 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526286, encodeId=aa8315262869a, content=<a href='/topic/show?id=84d03692056' target=_blank style='color:#2F92EE;'>#历史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36920, encryptionId=84d03692056, topicName=历史)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=131011702315, createdName=cathymary, createdTime=Tue Aug 31 12:13:08 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602381, encodeId=8005160238185, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Aug 31 12:13:08 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012714, encodeId=518e1012e1488, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Mon Aug 30 04:56:54 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012657, encodeId=fd3f101265e7f, content=<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>这是目前看到信息量最大，内容最全，也最新的一篇有关PROTAC新药开发的文章，值得收藏！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 29 22:07:26 CST 2021, time=2021-08-29, status=1, ipAttribution=)]
    2022-04-18 grace5700

    #TAC#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2121874, encodeId=709921218e4f3, content=新药研发利器<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>技术全面解析<a href='/topic/show?id=f259105e132a' target=_blank style='color:#2F92EE;'>#蛋白降解剂#</a>是十分热门的领域，事实上，很多老药现在发现实际上也是PROTAC类，如<a href='/topic/show?id=553b639416e' target=_blank style='color:#2F92EE;'>#氟维司群#</a>，<a href='/topic/show?id=21d764465c7' target=_blank style='color:#2F92EE;'>#沙利度胺#</a><a href='/topic/show?id=c34d64e47d1' target=_blank style='color:#2F92EE;'>#泊马度胺#</a>。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC), TopicDto(id=105713, encryptionId=f259105e132a, topicName=蛋白降解剂), TopicDto(id=63941, encryptionId=553b639416e, topicName=氟维司群), TopicDto(id=64465, encryptionId=21d764465c7, topicName=沙利度胺), TopicDto(id=64747, encryptionId=c34d64e47d1, topicName=泊马度胺)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun Mar 26 11:39:51 CST 2023, time=2023-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1672991, encodeId=c30416e29917e, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Mon Oct 18 04:13:08 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033744, encodeId=e1ed2033e44cf, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Mon Apr 18 22:13:08 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300486, encodeId=e67f1300486f4, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Tue Aug 31 12:13:08 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526286, encodeId=aa8315262869a, content=<a href='/topic/show?id=84d03692056' target=_blank style='color:#2F92EE;'>#历史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36920, encryptionId=84d03692056, topicName=历史)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=131011702315, createdName=cathymary, createdTime=Tue Aug 31 12:13:08 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602381, encodeId=8005160238185, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Aug 31 12:13:08 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012714, encodeId=518e1012e1488, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Mon Aug 30 04:56:54 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012657, encodeId=fd3f101265e7f, content=<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>这是目前看到信息量最大，内容最全，也最新的一篇有关PROTAC新药开发的文章，值得收藏！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 29 22:07:26 CST 2021, time=2021-08-29, status=1, ipAttribution=)]
    2021-08-31 lqvr

    #研发#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2121874, encodeId=709921218e4f3, content=新药研发利器<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>技术全面解析<a href='/topic/show?id=f259105e132a' target=_blank style='color:#2F92EE;'>#蛋白降解剂#</a>是十分热门的领域，事实上，很多老药现在发现实际上也是PROTAC类，如<a href='/topic/show?id=553b639416e' target=_blank style='color:#2F92EE;'>#氟维司群#</a>，<a href='/topic/show?id=21d764465c7' target=_blank style='color:#2F92EE;'>#沙利度胺#</a><a href='/topic/show?id=c34d64e47d1' target=_blank style='color:#2F92EE;'>#泊马度胺#</a>。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC), TopicDto(id=105713, encryptionId=f259105e132a, topicName=蛋白降解剂), TopicDto(id=63941, encryptionId=553b639416e, topicName=氟维司群), TopicDto(id=64465, encryptionId=21d764465c7, topicName=沙利度胺), TopicDto(id=64747, encryptionId=c34d64e47d1, topicName=泊马度胺)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun Mar 26 11:39:51 CST 2023, time=2023-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1672991, encodeId=c30416e29917e, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Mon Oct 18 04:13:08 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033744, encodeId=e1ed2033e44cf, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Mon Apr 18 22:13:08 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300486, encodeId=e67f1300486f4, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Tue Aug 31 12:13:08 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526286, encodeId=aa8315262869a, content=<a href='/topic/show?id=84d03692056' target=_blank style='color:#2F92EE;'>#历史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36920, encryptionId=84d03692056, topicName=历史)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=131011702315, createdName=cathymary, createdTime=Tue Aug 31 12:13:08 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602381, encodeId=8005160238185, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Aug 31 12:13:08 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012714, encodeId=518e1012e1488, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Mon Aug 30 04:56:54 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012657, encodeId=fd3f101265e7f, content=<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>这是目前看到信息量最大，内容最全，也最新的一篇有关PROTAC新药开发的文章，值得收藏！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 29 22:07:26 CST 2021, time=2021-08-29, status=1, ipAttribution=)]
    2021-08-31 cathymary

    #历史#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2121874, encodeId=709921218e4f3, content=新药研发利器<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>技术全面解析<a href='/topic/show?id=f259105e132a' target=_blank style='color:#2F92EE;'>#蛋白降解剂#</a>是十分热门的领域，事实上，很多老药现在发现实际上也是PROTAC类，如<a href='/topic/show?id=553b639416e' target=_blank style='color:#2F92EE;'>#氟维司群#</a>，<a href='/topic/show?id=21d764465c7' target=_blank style='color:#2F92EE;'>#沙利度胺#</a><a href='/topic/show?id=c34d64e47d1' target=_blank style='color:#2F92EE;'>#泊马度胺#</a>。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC), TopicDto(id=105713, encryptionId=f259105e132a, topicName=蛋白降解剂), TopicDto(id=63941, encryptionId=553b639416e, topicName=氟维司群), TopicDto(id=64465, encryptionId=21d764465c7, topicName=沙利度胺), TopicDto(id=64747, encryptionId=c34d64e47d1, topicName=泊马度胺)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun Mar 26 11:39:51 CST 2023, time=2023-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1672991, encodeId=c30416e29917e, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Mon Oct 18 04:13:08 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033744, encodeId=e1ed2033e44cf, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Mon Apr 18 22:13:08 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300486, encodeId=e67f1300486f4, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Tue Aug 31 12:13:08 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526286, encodeId=aa8315262869a, content=<a href='/topic/show?id=84d03692056' target=_blank style='color:#2F92EE;'>#历史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36920, encryptionId=84d03692056, topicName=历史)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=131011702315, createdName=cathymary, createdTime=Tue Aug 31 12:13:08 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602381, encodeId=8005160238185, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Aug 31 12:13:08 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012714, encodeId=518e1012e1488, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Mon Aug 30 04:56:54 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012657, encodeId=fd3f101265e7f, content=<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>这是目前看到信息量最大，内容最全，也最新的一篇有关PROTAC新药开发的文章，值得收藏！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 29 22:07:26 CST 2021, time=2021-08-29, status=1, ipAttribution=)]
    2021-08-31 sunylz

    #PRO#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2121874, encodeId=709921218e4f3, content=新药研发利器<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>技术全面解析<a href='/topic/show?id=f259105e132a' target=_blank style='color:#2F92EE;'>#蛋白降解剂#</a>是十分热门的领域，事实上，很多老药现在发现实际上也是PROTAC类，如<a href='/topic/show?id=553b639416e' target=_blank style='color:#2F92EE;'>#氟维司群#</a>，<a href='/topic/show?id=21d764465c7' target=_blank style='color:#2F92EE;'>#沙利度胺#</a><a href='/topic/show?id=c34d64e47d1' target=_blank style='color:#2F92EE;'>#泊马度胺#</a>。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC), TopicDto(id=105713, encryptionId=f259105e132a, topicName=蛋白降解剂), TopicDto(id=63941, encryptionId=553b639416e, topicName=氟维司群), TopicDto(id=64465, encryptionId=21d764465c7, topicName=沙利度胺), TopicDto(id=64747, encryptionId=c34d64e47d1, topicName=泊马度胺)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun Mar 26 11:39:51 CST 2023, time=2023-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1672991, encodeId=c30416e29917e, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Mon Oct 18 04:13:08 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033744, encodeId=e1ed2033e44cf, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Mon Apr 18 22:13:08 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300486, encodeId=e67f1300486f4, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Tue Aug 31 12:13:08 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526286, encodeId=aa8315262869a, content=<a href='/topic/show?id=84d03692056' target=_blank style='color:#2F92EE;'>#历史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36920, encryptionId=84d03692056, topicName=历史)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=131011702315, createdName=cathymary, createdTime=Tue Aug 31 12:13:08 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602381, encodeId=8005160238185, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Aug 31 12:13:08 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012714, encodeId=518e1012e1488, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Mon Aug 30 04:56:54 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012657, encodeId=fd3f101265e7f, content=<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>这是目前看到信息量最大，内容最全，也最新的一篇有关PROTAC新药开发的文章，值得收藏！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 29 22:07:26 CST 2021, time=2021-08-29, status=1, ipAttribution=)]
    2021-08-30 学医无涯

    了解一下

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2121874, encodeId=709921218e4f3, content=新药研发利器<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>技术全面解析<a href='/topic/show?id=f259105e132a' target=_blank style='color:#2F92EE;'>#蛋白降解剂#</a>是十分热门的领域，事实上，很多老药现在发现实际上也是PROTAC类，如<a href='/topic/show?id=553b639416e' target=_blank style='color:#2F92EE;'>#氟维司群#</a>，<a href='/topic/show?id=21d764465c7' target=_blank style='color:#2F92EE;'>#沙利度胺#</a><a href='/topic/show?id=c34d64e47d1' target=_blank style='color:#2F92EE;'>#泊马度胺#</a>。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC), TopicDto(id=105713, encryptionId=f259105e132a, topicName=蛋白降解剂), TopicDto(id=63941, encryptionId=553b639416e, topicName=氟维司群), TopicDto(id=64465, encryptionId=21d764465c7, topicName=沙利度胺), TopicDto(id=64747, encryptionId=c34d64e47d1, topicName=泊马度胺)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun Mar 26 11:39:51 CST 2023, time=2023-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1672991, encodeId=c30416e29917e, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Mon Oct 18 04:13:08 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033744, encodeId=e1ed2033e44cf, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Mon Apr 18 22:13:08 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300486, encodeId=e67f1300486f4, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Tue Aug 31 12:13:08 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526286, encodeId=aa8315262869a, content=<a href='/topic/show?id=84d03692056' target=_blank style='color:#2F92EE;'>#历史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36920, encryptionId=84d03692056, topicName=历史)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=131011702315, createdName=cathymary, createdTime=Tue Aug 31 12:13:08 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602381, encodeId=8005160238185, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Aug 31 12:13:08 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012714, encodeId=518e1012e1488, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Mon Aug 30 04:56:54 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012657, encodeId=fd3f101265e7f, content=<a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a>这是目前看到信息量最大，内容最全，也最新的一篇有关PROTAC新药开发的文章，值得收藏！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14751, encryptionId=c6f814e5136, topicName=PROTAC)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Aug 29 22:07:26 CST 2021, time=2021-08-29, status=1, ipAttribution=)]
    2021-08-29 病毒猎手

    #PROTAC#这是目前看到信息量最大，内容最全，也最新的一篇有关PROTAC新药开发的文章，值得收藏！！

    0

相关资讯

Arvinas靶向雌激素受体的蛋白质降解剂ARV-471治疗乳腺癌，其IND申请获FDA授权

Arvinas宣布其靶向雌激素受体（ER）的蛋白质降解剂ARV-471治疗局部晚期或转移性ER阳性/ HER2阴性乳腺癌的新药研究申请（IND），已经获得美国食品和药物管理局（FDA）的授权。Arvinas预计将在2019年第三季度开始ARV-471的1期临床试验。

J Med Chem: 双PROTAC来了：我国学者首次提出双重靶向降解（Dual PROTACs）药物设计新概念

近日，华中科技大学同济药学院李华教授、周宜荣副教授和沈阳药科大学无涯创新学院陈丽霞教授作为共同通讯作者，在药物化学顶级期刊 Journal of Medicinal Chemistry 发表了题为：R

Arvinas宣布启动1期临床研究，评估其靶向雌激素受体的PROTAC蛋白质降解剂ARV-471治疗乳腺癌的活性

Arvinas公司一直致力于开发靶向蛋白质降解的新型药物，宣布启动第二个临床计划。ARV-471（一种口服雌激素受体（ER）靶向PROTAC蛋白质降解剂）的1期临床试验将评估ARV-471在局部晚期或转移性ER阳性/ HER2阴性乳腺癌患者中的安全性、耐受性和药代动力学。